submit to the journals

Haematological Malignancies Journal Articles, Videos And Insights

Haematological Malignancies: FEATURED Articles

flipper_slider

Haematological Malignancies: Latest Articles

Haematological Malignancies: INSIGHTS

The touchONCOLOGY website provides a selection of resources to inform clinicians and patients about the latest developments in the field. The following are quick, non peer-reviewed, opinion-based updates addressing current trends and opinion on the most recent advances in the area of oncology:

Meeting Proceedings
Cytotoxic T Lymphocyte Therapy in the Treatment of Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder Katrina Mountfort
Senior Medical Writer, Touch Medical Media, Goring-on-Thames, UK
Insight
Acalabrutinib in Mantle Cell Lymphoma – New Long-term Data Announced Katrina Mountfort
Senior Medical Writer, Touch Medical Media, Goring-on-Thames, UK
Insight
CAR T-Cell Therapy for Relapsed or Refractory Large B-cell Lymphoma – Latest Data from the ZUMA-1 Study Katrina Mountfort
Senior Medical Writer, Touch Medical Media, Goring-on-Thames, UK

Haematological Malignancies: FEATURED VIDEOS

Editor's choice

touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic lymphocytic leukaemia (CLL) patients with alterations in the TP53 pathway represent an unmet clinical need? (0:10) 2. Could you tell us a little about venetoclax and its efficacy in CLL? (1:11) 3. What is the safety profile of venetoclax? (2:05) 4. What was the rationale for the investigation of the impact of clone size on outcomes in patients in the MURANO study? (2:56) 5. What were the findings of this investigation and what are the implications of these findings? (4:29) Speaker disclosures: Arnon P Kater has nothing to disclose in relation to this video interview. Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018.
Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in relapsed/refractory multiple myeloma? (0:09) 2. Could you tell us a little about the study design and what doses were used? (2:51) 3. What were the efficacy and safety findings of the combination? (4:22) 4. What other combined therapies are being considered for future studies? (5:10) Speaker disclosures: Paul Richardson has nothing to disclose in relation to this video interview. Filmed at the 23rd Annual Congress of the European Association of Hematology (EHA), Stockholm, Sweden, June 14–17 2018

Haematological Malignancies: Latest Videos

Video List based on Category on Node Page

Latest Videos

In this interview, filmed at ASH 2018, Dr Robin Foà talks to touchONCOLOGY about recent developments in the treatment of haematological malignancies, namely the identification of new genetic abnormalities, the increase in chemotherapy-free treatments, and the use of molecular technologies to...
Professor Nicolaus Kröger spoke to us at ASH 2018 about the major unmet needs in the treatment of myelodysplastic syndrome in elderly patients, and his phase III study comparing 5-azacytidine induction followed by allogeneic stem cell transplantation versus continuous 5-azacytidine according to...
touchONCOLOGY talks to Arnon P Kater from the Academisch Medisch Centrum Universiteit van Amsterdam about the MURANO study and the impact of TP53-mutated clone size on outcome of relapsed/refractory (R/R) CLL patients treated with venetoclax plus rituximab. 1. Why do chronic...
Annalisa Chiapella from Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino in Italy talks to touchONCOLOGY about patients with diffuse large B-cell lymphoma (DLBCL) with a TP53 mutation, and the aims and findings of the FIL-DLCL04 study to help tackle...
Paul Richardson from the Dana-Farber Cancer Institute and Harvard Medical School provides an overview of the key findings of the OPTIMISMM trial and discusses the need for new treatment strategies in multiple myeloma. 1. Why is there a need for new combinations of therapies in...
We catch up with editorial board member Willem Fibbe from Leiden University Medical Centre to discuss mesenchymal stromal cells and their therapeutic potential in the clinic. 1. What properties of mesenchymal stromal cells (MSCs) have led to the investigation of their therapeutic...

LATEST TWEETS

Conference Highlights